NCT03006172 2026-03-11To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerGenentech, Inc.Phase 1 Active not recruiting200 enrolled